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Introduction
Migraine is the most common acute intermittent primary headache in children that 
occurs in up to 10.6% of 5-15-year-old children (1).
During the past fifty years, several diagnostic criteria for pediatric migraine have 
been proposed and currently, second edition of the International Classification of 
Headache Disorders (ICHD-II) for children migraine that was published by the 
International Headache Society in 2004 has been accepted (2).
Preventive or prophylactic therapy is used in children with frequent (one or more 
headaches per week) or disabling (missing school, home or social activities, 
or a Pediatric Migraine Disability Assessment score (pedMIDAS) above 20) 
headaches (1).
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Abstract
Objective 
Migraine is the most common acute intermittent primary headache in children 
and prophylactic therapy is indicated in children with frequent or disabling 
headaches. The purpose of this study was to evaluate the efficacy and safety of 
topiramate (TPM) for migraine prophylaxis in children.
Materials & Methods
In a quasi-experimental study, monthly frequency, severity and duration of 
headache, migraine disability, and side-effects were evaluated in 100 children 
who were referred to the Pediatric Neurology Clinic of Shahid Sadoughi 
University of Medical Sciences, Yazd, Iran from April 2011 to March 2012, and 
were treated with 3 mg/kg/day of TPM for three months. 
Results
Fifty eight (57.4%) girls and 42 (41.6%) boys with the mean age of 10.46±2.11 
years were evaluated. Monthly frequency, severity, and duration of headache 
decreased with treatment from 15.34±7.28 to 6.07±3.16 attacks, from 
6.21±1.74 to 3.15±2.22, and from 2.28±1.55 to 0.94±0.35 hours, respectively, 
and the Pediatric Migraine Disability Assessment score reduced with TPM 
from 32.48±9.33 to 15.54±6.16. Transient side-effects were seen in 21% of 
the patients, including hyperthermia in 11%, anorexia and weight loss in 6%, 
and drowsiness in 4%. No serious side-effects were reported.
Conclusion
TPM could be considered as a safe and effective drug in pediatric migraine 
prophylaxis. 
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Preventive medications, including calcium channel 
blockers, cyproheptadine, beta blockers and 
anticonvulsants have been used in children (3).
Recently, antiepileptic drugs are more commonly used 
in adults and adolescents for migraine prophylactic 
therapy (1).
Topiramate (TPM) is an antiepileptic drug that the exact 
mechanism of its effectiveness in migraine is unclear. 
However, its migraine preventive effect may be based 
on the following mechanisms: 
a) inhibition of excitatory neurotransmission by 
blocking glutamate at a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid–kainate receptors
b) enhancing the inhibitory activity of γ-aminobutyric 
acid receptors 
c) blocking voltage-dependent sodium channels 
d) blocking high-voltage–activated calcium channels 
e) inhibition of erythrocyte carbonic anhydrase (4). 
Safety of TPM in Iranian epileptic children has been 
reported as well (5). There are limited studies about 
efficacy of TPM for migraine prevention in children in 
Iran.
The purpose of this study was to evaluate the efficacy 
and safety of TPM for migraine prophylaxis in children 
in Yazd, central city of I.R. Iran. 
Materials & Methods
This quasi-experimental (before and after) study was 
conducted on 5-15-year old migraineurs, who were 
referred to Pediatric Neurology Clinic of Shahid 
Sadoughi University of Medical Sciences, Yazd, Iran 
from April 2011 to June 2012.
Sample size was assessed to be 100 children based on 
Z formula and a confidence interval of 95% with 80% 
power to detect a 20% difference in efficacy between the 
two groups with type one error (alpha) of 0.05.
Eligible participants included those children aged 5-15 
years, had migraine headache based on ICHD-II criteria 
(2) in clinical evaluation by pediatric neurologist for 
at least six months before the study, used no migraine 
preventive therapy, and had frequent (one or more 
headache attacks per week) or disabling (PedMIDAS 
more than 20) headaches that prophylactic therapy was 
indicated for them.
Exclusion criteria consisted of presence of metabolic 
acidosis, kidney dysfunction, renal stone, any serious 
systemic diseases, headaches other than migraine and 
secondary headaches, or those who did not complete the 
three-month period of treatment.
Headaches other than migraine, secondary headaches, 
and systemic diseases were excluded by pediatric 
neurologist clinical evaluation of patients through taking 
history, physical examination, laboratory evaluation if 
indicated, and brain magnetic resonance imaging when 
increased intracranial pressure was suspected, either by 
historical suspicion or physical exam (1).
Patients were treated with 3 mg/kg/day of TPM in two 
divided doses. Children were visited for three consecutive 
months and clinical information about frequency, 
severity, and duration of headaches, pedMIDAS score 
(6) and drug side-effects were recorded. 
Severity of headache was assessed by asking each child 
to grade majority of headache pain on visual analogue 
scale (VAS) (7) on a 10-point scale as no pain=scale of 
0 and the most severe pain=10. A VAS is a horizontal or 
vertical 10-cm length line that is marked at the extremes 
by “no pain” and “worst pain imaginable”. The children 
were asked to place a mark on the line that showed their 
pain level. 
Monthly frequency, severity and duration of headache, 
and pedMIDAS were evaluated before and three 
months after TPM therapy.
More than 50% of reduction in monthly headache 
frequency was considered as good response.
Clinical side-effects of TPM in the duration of treatment 
were recorded through interviewing the parents of the 
patients.
The data were analyzed using SPSS 17 statistical 
software. Chi-square test was used for analysis of 
qualitative variables and mean values were compared 
using T-test. Differences were considered significant at 
p-values of less than 0.05.
Informed consent was taken from patients’ parents and 
the study has been approved by the Ethics Committee of 
Shahid Sadoughi University of Medical Sciences, Yazd, 
Iran.
The researchers got no support from drug companies. 
Results
Fifty eight (57.4%) girls and 42(41.6%) boys with the 
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In this study, TPM was effective in improvement of 
headache disability by reduction of pedMIDAS score 
which is in agreement with other studies (16,17). 
In our study, both drugs were safe and no serious clinical 
adverse event was seen in the two groups. Safety of TPM 
has also been reported in other researches (10,11,17,18).
In this study, in children taking TPM, side effects 
including hyperthermia in 11%, anorexia and weight loss 
in 6% and drowsiness in 4% were seen and all of these 
side effects were mild and transient and not significant 
enough to exclude from the study.
Weight loss was the most common side-effects in two 
other studies (10,17).
In Lewis et al.’s study, upper respiratory tract infection, 
paresthesia, and dizziness were more frequently in TPM 
than placebo group (11).
In a study in Barcelona, 33.3% of children who were 
treated with TPM showed side-effects, none of which 
were serious (13).
In Winner et al.’s study, upper respiratory tract infection, 
anorexia, weight loss, gastroenteritis, paresthesia and 
drowsiness were more frequently in TPM than placebo 
group (10).
In Cruz et al.’s study, 27% of 7.3-20.5 year migraineurs 
who were treated with TPM had side-effects and 
drug dose was more in patients with adverse effects 
(2.8±1.5 mg/kg/day vs. 1.27±0.7 mg/kg/day) (14).
In an Indian study, weight loss, reduced concentration in 
school, drowsiness, and parasthesia were more important 
adverse effects of TPM (17). 
TPM may also cause cognitive and concentration 
dysfunction (17, 19).
The limitations of the present study were lack of placebo 
and no assessment of children’s cognitive function.
In conclusion, based on results of the present study, 
TPM is a safe and effective drug for pediatric migraine 
prophylaxis in reduction of monthly frequency, severity, 
duration, and disability of migraine headache in children. 
mean age of 10.46±2.11 years were evaluated. Onset age 
of headache was 4-14 years (mean±SD: 9.96±8.16 years). 
After three months of treatment, good response (more 
than 50% reduction in monthly headache frequency) 
was seen in 74% of children (95% confidence interval 
of 0.71-0.93). 
Frequency distribution of the good response based on 
some characteristics of the children is shown in Table 
1, which indicates that no statistically significant 
differences were seen in terms of sex distribution, 
migraine type, positive family history of migraine, mean 
of age, and mean of onset age of migraine between the 
two groups. 
Table 2 shows headache characteristics before and 
after TPM treatment which indicates that the drug was 
effective in reduction of monthly frequency, severity, 
duration, and disability of headache. 
No serious adverse events were seen in the patients, but 
transient and mild clinical side-effects were observed 
in 21% (N=21) of children, including hyperthermia in 
11, anorexia and weight loss in 6, and drowsiness in 
4 children. All side-effects disappeared in one or two 
weeks and treatment was stopped in none of the patients 
who suffered from the side-effects.
Discussion
Various drugs have been used for migraine prophylaxis 
in children. In the present study, efficacy and safety of 
TPM was evaluated and the results showed that TPM is 
effective in the reduction of monthly frequency, severity, 
duration, and disability of headache which is in agreement 
with another Iranian study on adult migraineurs. In this 
study, duration of headache decreased from 2.28±1.55 
to 0.94±0.35 hours, but in a study by Ashtari et al. in 
Isfahan, Iran, headache duration decreased with TPM 
treatment from 16.37±7.26 to 6.23±5.22 hours (9). In 
children, duration of migraine headache was shorter than 
adult (2).
In the present study, more than 50% of the reduction in 
monthly headache frequency was attained with TPM in 
74% of patients. However, in other studies, the proportion 
whose monthly headache frequency decreased more 
than 50% varied from 55% to 100% (10-15). Possible 
explanations for these discrepancies are differences in 
age, drug dosage, race, sample size, and design of study.
Topiramate in  Childhood Migraine Prophylaxis 
10 Iran J Child Neurol. 2013 Autumn Vol 7 No 4 













Without aura 46 15
0.44
With aura 25 11




Age in year (mean ±SD) 10.30±2.17 10.92±2.24 0.22
Age of onset migraine (mean ±SD) 8.25±2.36 8.92±2.01 0.20
 





After treatment (Mean 
± SD)
p-value
Monthly headache frequency 15.34±7.28 6.07±3.16 0.0001
Severity of headache 6.21±1.74 3.15±2.22 0.001
Headache duration in hours 2.28±1.55 0.94±0.35 0.002
Headache disability: pedMIDAS 32.48±9.33 15.54±6.16 0.0001
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